PolyNovo
| Public company | |
| Traded as | ASX: PNV |
| ISIN | 🆔 |
| Industry | Medical Devices |
| Founded 📆 | 2004 |
| Founder 👔 | |
Area served 🗺️ | Global |
| Products 📟 | NovoSorb BTM, NovoSorb MTX |
| Revenue🤑 | 103.23 million AUD |
| Members | |
Number of employees | 300 |
| 🌐 Website | polynovo.com |
| 📇 Address | |
| 📞 telephone | |
PolyNovo is a company that specializes in developing innovative medical devices using its proprietary biodegradable polymer technology, NovoSorb™. The company focuses on creating regenerative tissue solutions and has a range of products designed for advanced wound care and reconstructive surgery.[1][2]
PolyNovo was established on February 27, 2004, with the aim of commercializing its biodegradable polymer technology. The original patent applications for NovoSorb™ were based on technology developed by CSIRO Division of Molecular and Health Technologies and were assigned to PolyNovo. The company has since developed additional patents and has partnered with some of the world's leading medical device companies.
PolyNovo's products are currently distributed in 29 countries[3], and the company is publicly traded on the Australian Stock Exchange (ASX:PNV). The company employs approximately 150 people at its head office and manufacturing facility located in Port Melbourne, Victoria.
Company history
PolyNovo is a commercial-stage medical device company that develops innovative solutions using its patented bioabsorbable polymer technology, NovoSorb®. The company focuses on improving patient outcomes through the development and provision of revolutionary synthetic skin substitutes.
Products
NovoSorb BTM (Biodegradable Temporizing Matrix): A dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. NovoSorb BTM has received FDA 510(k) clearance and is commercialized in the United States, Europe, and other regions.
NovoSorb MTX: Another product in the NovoSorb family, designed for various medical applications.
Milestones
2004: PolyNovo was founded. 2015: NovoSorb BTM received FDA 510(k) clearance and was awarded significant funding from the US-based Biomedical Advanced Research and Development Authority (BARDA) for trials. 2024: PolyNovo continues to expand its manufacturing facility and headquarters in Melbourne, Australia, establishing high-quality processes and preparing for growth.
Market Presence
PolyNovo products are currently distributed in 29 countries. The company is publicly traded on the Australian Stock Exchange under the ticker symbol ASX: PNV.
References
- ↑ {{Cite news|url = https://www.medicaldevice-network.com/featured-company/2023-polynovo/%7Ctitle = Medical Device Network Excellence Awards 2023: PolyNovo}
- ↑ {{Cite news|url = https://www.marketscreener.com/quote/stock/POLYNOVO-LIMITED-19156795/company/ | title = PolyNovo Limited}
- ↑ {{Cite news|url = https://www.medicaldevice-network.com/featured-company/2023-polynovo/ | title = Medical Device Network Excellence Awards 2023: PolyNovo}
This article "PolyNovo" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:PolyNovo. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
